Towards Healthcare
U.S. CAR T-Cell Therapies Market Trends and Companies

U.S. CAR T-Cell Therapies Market Advances with New Deals

The U.S. CAR T-Cell Therapies Market is growing, as this therapy has high efficacy against blood cancers, robust research and development, and government bodies are accelerating the approval process for novel therapies.

Content

  • Last Updated: 20 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The U.S. CAR T-cell therapies market is set for robust growth, fueled by rising investments and innovation, with revenue projections reaching hundreds of millions by 2034.

The U.S. CAR T-cell therapies market includes four segments by drug type, by indication, by end user, and by region.

Some key players include Lonza, Aurora Biopharma, Cartesian Therapeutics, Inc., Novartis, and Bristol-Myers Squibb Company.

Most patients recovered within six months to a year after CAR T-cell therapy. But there are reports of some patients actually having low immunoglobulins years after CAR T-cells and B-cell aplasia for four or five years after CAR T-cells.

National Institutes of Health, FDA, WHO, PIB, CDC, National Cancer Institutes.
Any Questions